Collagen/calcium phosphate and bone marrow aspirate in new bone formation at the mandible jaw

Bone ◽  
2008 ◽  
Vol 42 ◽  
pp. S27-S28
Author(s):  
Victor P. Palarie
Keyword(s):  
Bone Marrow ◽  
Calcium Phosphate ◽  
Bone Formation ◽  
Bone Marrow Aspirate ◽  
New Bone Formation

Bone Marrow Autograft Associated to Macroporous Biphasic Calcium Phosphate for Bone Substitution in an Animal Model of Sequels of Radiotherapy

2005 ◽  
Vol 284-286 ◽  
pp. 285-288
Author(s):  
Oliver Malard ◽  
Jean Michel Bouler ◽  
Jerome Guicheux ◽  
Olivier Gauthier ◽  
E. Lerouxel ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Calcium Phosphate ◽  
Bone Formation ◽  
Biphasic Calcium Phosphate ◽  
Bone Repair ◽  
Major Surgery ◽  
Graft Versus Host Reaction ◽  
Bone Reconstruction ◽  
New Bone Formation ◽  
Study Results

Bone invasion is common in case of Squamous Cell Carcinomas (SCC) of the upper aero-digestive tract. Radiotherapy is required in addition to large surgical tumor removal. This treatment usually generates irreversible injuries on the reparation properties of the tissues, especially on bone. The quality of life of patients undergoing major surgery and radiotherapy in maxillary and mandible areas is reduced, but could be improved by bone reconstruction. The aim of this study was to evaluate the bone reconstruction possibilities by Macroporous Biphasic Calcium-Phosphate (MBCPÔ). The MBCP substitute was evaluated as granules and associated to autologous bone marrow (BM) graft in irradiated areas, in an inbreeding rodent model. Radiation sequels were created on inferior members of half of the rats. 3 weeks later, 3-mm osseous defects were created on each animal. The inbreeding model allows BM to be grafted without graft-versus-host reaction. Defects were filled either with MBCP alone, BM alone or a mixture of MBCP and BM. Six weeks after implantation, animals were sacrificed: bone repair and ceramic degradation were evaluated by qualitative and quantitative study. Results showed that bioceramics were well osteointegrated. Filling the defects with BM alone showed a significant increased of newly-formed bone formation but only after irradiation, whereas filling defects with MBCP alone increased new-bone formation only without previous irradiation. Associating MBCP to BM provided the best new-bone formation rates after irradiation. Degradation of the ceramic was the most important in case of BM grafting. This study demonstrated that BM added to MBCP constitute an appropriate material to be considered in case of bone defect occurring in irradiated tissue, and could be foreseen for use after bone removal for oncologic obligations.

scholarly journals Topical co‐administration of zoledronate with recombinant human bone morphogenetic protein-2 can induce and maintain bone formation in the bone marrow environment

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Hideki Ueyama ◽  
Yoichi Ohta ◽  
Yuuki Imai ◽  
Akinobu Suzuki ◽  
Ryo Sugama ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Formation ◽  
Bone Structure ◽  
Precursor Cells ◽  
The Other ◽  
Bone Morphogenetic Protein 2 ◽  
New Bone Formation ◽  
Micro Computed Tomography ◽  
Mineral Density ◽  
Left Femur

Abstract Background Bone morphogenetic proteins (BMPs) induce osteogenesis in various environments. However, when BMPs are used alone in the bone marrow environment, the maintenance of new bone formation is difficult owing to vigorous bone resorption. This is because BMPs stimulate the differentiation of not only osteoblast precursor cells but also osteoclast precursor cells. The present study aimed to induce and maintain new bone formation using the topical co-administration of recombinant human BMP-2 (rh-BMP-2) and zoledronate (ZOL) on beta-tricalcium phosphate (β-TCP) composite. Methods β-TCP columns were impregnated with both rh-BMP-2 (30 µg) and ZOL (5 µg), rh-BMP-2 alone, or ZOL alone, and implanted into the left femur canal of New Zealand white rabbits (n = 56). The implanted β-TCP columns were harvested and evaluated at 3 and 6 weeks after implantation. These harvested β-TCP columns were evaluated radiologically using plane radiograph, and histologically using haematoxylin/eosin (H&E) and Masson’s trichrome (MT) staining. In addition, micro-computed tomography (CT) was performed for qualitative analysis of bone formation in each group (n = 7). Results Tissue sections stained with H&E and MT dyes revealed that new bone formation inside the β-TCP composite was significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). Micro-CT data also demonstrated that the bone volume and the bone mineral density inside the β-TCP columns were significantly greater in those impregnated with both rh-BMP-2 and ZOL than in those from the other experimental groups at 3 and 6 weeks after implantations (p < 0.05). Conclusions The topical co-administration of both rh-BMP-2 and ZOL on β-TCP composite promoted and maintained newly formed bone structure in the bone marrow environment.

scholarly journals New Bone Formation in Tuberculous-Infected Vertebral Body Defect after Administration of Bone Marrow Stromal Cells in Rabbit Model

2016 ◽  
Vol 10 (1) ◽  
pp. 1 ◽  
Author(s):  
Ahmad Jabir Rahyussalim ◽  
Tri Kurniawati ◽  
Nurjati Chairani Siregar ◽  
Agus Syahrurachman ◽  
Ismail Hadisubroto Dilogo ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Formation ◽  
Vertebral Body ◽  
Stromal Cells ◽  
Bone Marrow Stromal Cells ◽  
Rabbit Model ◽  
Marrow Stromal Cells ◽  
New Bone Formation

In Vitro and In Vivo Evaluation Of Calcium Phosphate Bone Graft Substitutes

2010 ◽  
Vol 654-656 ◽  
pp. 2065-2070
Author(s):  
Ho Yeon Song ◽  
Young Hee Kim ◽  
Jyoti M. Anirban ◽  
In Seon Byun ◽  
Kyung A Kwak ◽  
...  
Keyword(s):  
Calcium Phosphate ◽  
Bone Formation ◽  
Bone Graft ◽  
Cellular Proliferation ◽  
New Bone Formation ◽  
Hydroxy Apatite ◽  
Defect Sites ◽  
Bone Graft Substitutes

Calcium phosphate ceramics such as hydroxy apatite (HA), β-tricalcium phosphate (β-TCP) and bicalcium phosphate (BCP) have been used as a bone graft biomaterial because of their good biocompatibility and similarity of chemical composition to natural bones. To increase the mechanical and osteoconductive properties, the granules and spongy type porous bone graft substitutes were prepared by fibrous monolithic process and polyurethane foam replica methods, respectively. The pore sizes obtained using these approaches ranged between 100-600 µm. The cytotoxicity, cellular proliferation, differentiation and ECM deposition on the bone graft substitutes were observed by SEM and confocal microscopy. Moreover, the scaffolds were implanted in the rabbit femur. New bone formation and biodegradation of bone graft were observed through follow-up X-ray, micro-CT analysis and histological findings. After several months (2, 3, 6, 12 and 24 months) of implantation, new bone formation and ingrowths were observed in defect sites of the animal by CaP ceramics and 2 to 3 times higher bone ingrowths were confirmed than that of the normal trabecular bones in terms of total bone volume (BV).

Effect of Particle Size on New Bone Formation In Vivo Using Calcium Phopshate Glass

2007 ◽  
Vol 330-332 ◽  
pp. 165-168
Author(s):  
Hyun Ju Moon ◽  
Racquel Z. LeGeros ◽  
Kyoung Nam Kim ◽  
Kwang Mahn Kim ◽  
Seong Ho Choi ◽  
...  
Keyword(s):  
Particle Size ◽  
Calcium Phosphate ◽  
Bone Formation ◽  
Phosphate Glass ◽  
Glass Powder ◽  
New Bone Formation ◽  
Sprague Dawley ◽  
Constant Weight ◽  
Calvarial Defects

The purpose of this study was to compare the bone regenerative effect of calcium phosphate glass according to the particle size in vivo. We prepared two different sizes, that is 400 μm and 40 μm, of calcium phosphate glass powder using the system CaO-CaF2-P2O5-MgO-ZnO. Critical-sized calvarial defects were created in 60 male Sprague-Dawley rats. The animals were divided into 3 groups of 20 animals each. Each defect was filled with a constant weight of 0.5 g calcium phosphate glass powder mixed with saline. As controls, the defect was left empty. The rats were sacrificed 2 or 8 weeks after postsurgery, and the results were evaluated using histological as well as histomorphometrical studies. The particle size of the calcium phosphate was crucial; 400 μm particles promoted new bone formation, while 40 μm particles inhibited it because of severe inflammation.

Myeloma Cells Switch Osteoblastogenesis to Adipogenesis and Suppress Bone Formation

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 3386-3386 ◽  
Author(s):  
Jing Yang ◽  
Zhiqiang Liu ◽  
Huan Liu ◽  
Jin He ◽  
Pei Lin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Formation ◽  
Osteoblast Differentiation ◽  
Conflicts Of Interest ◽  
Bone Destruction ◽  
Current Treatment ◽  
New Bone Formation ◽  
Myeloma Cells ◽  
Dickkopf 1

Abstract Bone destruction is a hallmark of myeloma, and has a severe impact on patients’ quality of life and survival. Unfortunately, current treatment only offers moderate palliative effects, and this disease remains incurable. The bone changes in myeloma patients results from increased osteoclast-mediated bone resorption and decreased osteoblast-mediated bone formation. In particular, new bone formation that usually occurs at sites of previously resorbed bones is deeply suppressed; as a result, areas of bone destruction rarely heal. Previous studies have shown that myeloma cells inhibit osteoblast differentiation from mesenchymal stem cells (MSCs), and the Wnt/b-catenin signaling pathway is suppressed via myeloma-produced Wnt antagonists such as dickkopf-1. However, the role of dickkopf-1 in myeloma-induced inhibition of bone formation remains controversial since myeloma cells alone do not produce sufficient dickkopf-1 to suppress osteoblast differentiation. In addition, the administration of an antibody against dickkopf-1 in myeloma patients failed to restore new bone formation, indicating there must be an additional mechanism for inhibition of osteoblast differentiation seen in myeloma. While MSCs can differentiate into mature osteoblasts, they are also capable of differentiating into adipocytes, which is a major cell type in marrow stroma. We observed that myeloma cells (cell lines and primary cells isolated from myeloma patients’ bone marrow) injected into human or mouse bone not only reduced osteoblast number, but also increased adipocyte number and activity in bone marrow. Similar observations were seen in the clinical setting where collections of adipocytes were found in the bone marrow of newly diagnosed, untreated myeloma patients. Patients with greater bone destruction had higher adipocyte numbers than those in patients with less bone destruction, indicating a relationship among myeloma cells, adipogenesis, and osteoblastogenesis. We hypothesized that inhibition of osteoblast differentiation is a consequence of myeloma-dependent alterations in the control of the MSCs’ fate into osteoblasts or into adipocytes. In our studies, we co-cultured MSCs with myeloma cells in a mixed medium (that contained both adipocyte and osteoblast media), and we observed co-culture with myeloma cells induced more adipocyte than osteoblast formation. Moreover, co-culture with myeloma cells enhanced adipocyte differentiation in vitro. Interestingly, separation of the cells by transwell inserts significantly reduced such effect. By analysis of the adhesion molecules in myeloma cells, we identified integrin α4β1 as a novel contributor in regulation of adipogenesis and osteoblastogenesis. Thus, our studies indicate that in the presence of myeloma cells, MSCs may be more prone to differentiate into adipocytes than into osteoblasts via α4β1. Our studies also suggest the development of new strategies to improve the care of myeloma patients with bone destruction by targeting α4β1 and its signaling pathways. Disclosures No relevant conflicts of interest to declare.

scholarly journals Safety of autologous bone marrow aspiration concentrate transplantation: initial experiences in 101 patients

2009 ◽  
Vol 1 (1) ◽  
pp. 32 ◽  
Author(s):  
Christian Hendrich ◽  
Franz Engelmaier ◽  
Gerhart Waertel ◽  
Rolf Krebs ◽  
Marcus Jäger
Keyword(s):  
Bone Marrow ◽  
Cell Therapy ◽  
Bone Formation ◽  
Ex Vivo ◽  
Bone Marrow Aspiration ◽  
Tumor Formation ◽  
Surveillance Study ◽  
New Bone Formation ◽  
Technical Effort

The clinical application of cellular based therapies with ex vivo cultivation for the treatment of diseases of the musculoskeletal system has until now been limited. In particular, the advanced laboratory and technical effort necessary, regulatory issues as well as high costs are major obstacles. On the other hand, newly developed cell therapy systems permit intra-operative enrichment and application of mesenchymal and progenitor stem cells from bone marrow aspirate concentrate (BMAC) in one single operative session. The objective of the present clinical surveillance study was to evaluate new bone formation after the application of BMAC as well as to record any possible therapy-specific complications For this purpose, the clinical-radiological progress of a total of 101 patients with various bone healing disturbances was documented (surveillance study). The study included 37 necrosis of the head of the femur, 32 avascular necroses/bone marrow edema of other localization, 12 non-unions, 20 other defects. The application of BMAC was performed in the presence of osteonecrosis via a local injection as part of a core decompression (n=72) or by the local adsorption of intra-operative cellular bone substitution material (scaffold) incubated with BMAC during osteosynthesis (n=17) or in further surgery (n=12). After an average of 14 months (2-24 months), the patients were re-examined clinically and radiologically and interviewed. Further surgery was necessary in 2 patients within the follow-up period. These were due to a progression of a collapsed head of the femur with initial necrosis in ARCO Stage III, as well as inadequate new bone formation with secondary loss of correction after periprosthetic femoral fracture. The latter healed after repeated osteosynthesis plus BMAC application without any consequences. Other than these 2 patients, no further complications were observed. In particular, no infections, no excessive new bone formation, no induction of tumor formation, as well as no morbidity due to the bone marrow aspiration from the iliac crest were seen. There were no specific complications within the short follow-up period and a simple intra-operative use of the system for different forms of bone loss could be demonstrated. In the authors’ opinion, the on-site preparation of the bone marrow cells within the operating theater eliminates the specific risk of ex vivo cell proliferation and has a safety advantage in the use of autologous cell therapy for bone regeneration. Additional studies should be completed to determine efficacy.

Sign in / Sign up

Export Citation Format

Share Document